Nasdaq · CIK 0001833141
HELP Helus Pharma Inc.
Insider trading from SEC Form 4. Last filing 12 d ago. Close $11.80 on Oct 9, 2026, +205% from the 52-week low and -16% from the high.
In brief
Helus Pharma Inc. (HELP) has 11 SEC Form 4 filings on file from 4 insiders, the latest filed on Oct 1, 2026. In the last 90 days insiders made 9 open-market buys worth $9.7M and 0 open-market sells worth $0, net +$9.7M.
9 open-market trades have been scored at HELP. The newest: Greg Cavers (Chief Financial Officer) bought $39k of stock on Sep 29, 2026, filed Oct 1, 2026, scored 44 (moderate). The largest of the 9 shown: Michael Halstead (Chief Executive Officer) bought $1.3M on Sep 21, 2026, scored 75 (notable). 2 insiders bought within 14 days of each other around Sep 29, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Helus Pharma Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | Greg Cavers Chief Financial Officer buy | $39k 3,000 shares | - | +228% from low-9% from high | |
| 75Notable | Michael Halstead Chief Executive Officer buy | $1.3M 100,000 shares | +146% | +253% from low-3% from high | |
| 65Notable | Eric H. L. So Executive Chair buy | $1.2M 100,000 shares | +2% | - | |
| 60Notable | Paul Glavine Chief Growth Officer buy | $1.2M 100,000 shares | +2% | - | |
| 60Notable | Paul Glavine Chief Growth Officer buy | $1.2M 100,000 shares | +2% | - | |
| 53Moderate | Paul Glavine Chief Growth Officer buy | $1.2M 100,000 shares | +2% | - | |
| 58Moderate | Eric H. L. So Executive Chair buy | $1.2M 100,000 shares | +2% | - | |
| 48Moderate | Paul Glavine Chief Growth Officer buy | $1.0M 90,000 shares | +2% | - | |
| 53Moderate | Eric H. L. So Executive Chair buy | $1.1M 95,000 shares | +2% | - |
Transactions
Every row filed, 11 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Paul Glavine Chief Growth Officer | AGrant or award Common Shares | +248,000 | - | - | 4,750,191 | 12 d ago |
| Sep 30, 2026 | Eric H. L. So Executive Chair | AGrant or award Common Shares | +248,000 | - | - | 4,713,014 | 12 d ago |
| Sep 29, 2026 | Greg Cavers Chief Financial Officer | POpen-market purchase Common Sharesindirect: Held by spouse | +3,000 | $12.91 | $39k | 3,000 | 12 d ago |
| Sep 21, 2026 | Michael Halstead Chief Executive Officer | POpen-market purchase Common Shares | +100,000 | $13.47 | $1.3M | 168,568 | 22 d ago |
| Sep 8, 2026 | Eric H. L. So Executive Chair | POpen-market purchase Common Shares | +100,000 | $12.39 | $1.2M | 4,465,014 | 32 d ago |
| Sep 8, 2026 | Paul Glavine Chief Growth Officer | POpen-market purchase Common Shares | +100,000 | $12.47 | $1.2M | 4,271,252 | 32 d ago |
| Sep 8, 2026 | Paul Glavine Chief Growth Officer | POpen-market purchase Common Shares | +100,000 | $12.47 | $1.2M | 4,271,252 | 32 d ago |
| Sep 4, 2026 | Eric H. L. So Executive Chair | POpen-market purchase Common Shares | +100,000 | $12.09 | $1.2M | 4,365,014 | 33 d ago |
| Sep 3, 2026 | Paul Glavine Chief Growth Officer | POpen-market purchase Common Shares | +100,000 | $11.78 | $1.2M | 4,171,252 | 33 d ago |
| Sep 1, 2026 | Eric H. L. So Executive Chair | POpen-market purchase Common Shares | +95,000 | $11.81 | $1.1M | 4,265,014 | 34 d ago |
| Aug 31, 2026 | Paul Glavine Chief Growth Officer | POpen-market purchase Common Shares | +90,000 | $11.59 | $1.0M | 4,071,252 | 34 d ago |
Insiders
Everyone who has filed a Form 4 here.
- Greg CaversChief Financial Officer
- Paul GlavineChief Growth Officer
- Michael HalsteadChief Executive Officer
- Eric H. L. SoExecutive Chair
Questions about HELP
Answered from the filings on this page, as of the latest one.
Are insiders buying HELP?
As of Oct 1, 2026, SEC Form 4 filings show 9 open-market buys worth $9.7M by 4 insiders and 0 open-market sells worth $0 by 0 insiders at Helus Pharma Inc. in the last 90 days, net +$9.7M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade HELP on the open market?
Greg Cavers (Chief Financial Officer) bought $39k of HELP on Sep 29, 2026 and filed the Form 4 on Oct 1, 2026. InsiderTell scored 44 (moderate), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Helus Pharma Inc.?
4 people have filed a Form 4 at Helus Pharma Inc., among them Greg Cavers (Chief Financial Officer), Paul Glavine (Chief Growth Officer), Michael Halstead (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.